Upgrades must flow in.
Apparently not. Missed on profit, $.04 versus estimate of $.06 a share. Guidance for Q3 is for $.04 again. Plus, with $30 million shelf overhanging, hard to see a new term catalyst to buy. Okay for patient money.
Overall breadth was positive and market always looks forward. PCI sales were good and they talked about disruptive technology they have if you heard the conf call. expecting upgrades